Optimizing ASCT in Patients With Multiple Myeloma and Non-Hodgkin’s Lymphoma Through Stem Cell Mobilization Techniques

This online, on-demand virtual symposium brings together renowned experts to discuss stem cell mobilization for autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) or lymphoma. In this educational program, these experts discuss optimization of stem cell mobilization, including strategies to improve the success of ASCT in eligible patients using illustrative clinical scenarios.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi US.

Target Audience

This educational program is directed toward hematologists, oncologists, blood and marrow transplant (BMT) specialists, BMT nurses, and other clinicians involved in the treatment of patients with MM and non–Hodgkin lymphoma (NHL).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain established protocols designed for stem cell mobilization in patients with MM and NHL undergoing ASCT
  • Evaluate recent clinical trial evidence on agents intended to improve the efficacy of stem cell mobilization
  • Apply strategies to mitigate treatment-related toxicities and optimize stem cell mobilization outcomes
  • Translate recent data on agents promoting stem cell mobilization to formulate personalized treatment plans for patients with MM and NHL undergoing ASCT
Additional information


Jani Sharma
Phone Number: 
+1 (732) 841-0077
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
Course expires: 
Luciano J. Costa, MD, PhD
Director Multiple Myeloma Program
Associate Director for Clinical Research
O’Neal Comprehensive Cancer Center
Professor of Medicine
The University of Alabama at Birmingham
Birmingham, AL
Disclosures: Grant/Research Support: Amgen, Janssen, Bristol Myers Squibb; Consultant: Amgen, Janssen, Bristol Myers Squibb, Sanofi, Adaptive Biotechnologies; Speakers’ Bureau: Amgen, Sanofi.
Paul Shaughnessy, MD
Program Medical Director
Sarah Cannon Transplant and Cellular Therapy Program
Methodist Hospital
Assistant Professor of Medicine
University of Texas Health Science Center
San Antonio, TX
Disclosures: Speakers’ Bureau: Sanofi, Bristol Myers Squibb, Kite, a Gilead Company.

MCW and PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This activity is co-provided with our educational partner, Physician Education Resource (PER)

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.


Please login or register to take this course.